1xbet 카지노

Tokyo, Japan, December 10, 2010 -- Otsuka Pharmaceuti1xbet 카지노l Co., Ltd. today announced that it will launch Sams1xbet 카지노^® Tablets 15mg (tolvaptan), a V₂-vasopressin receptor antagonist, in Japan on December 14, 2010. Samsca is t1xbet 카지노 world's first aquaretic treatment for volume overload in patients with 1xbet 카지노art failure, with a mechanism of action to increase free water excretion without an accompanying increase in electrolyte excretion.

Sams1xbet 카지노 is a nonpeptide vasopressin V₂-receptor antagonist discovered by Otsuka Pharmaceutical, with a unique mechanism of action that selectively blocks t1xbet 카지노 binding of vasopressin, an antidiuretic hormone, to t1xbet 카지노 V₂-receptors in t1xbet 카지노 collecting duct of t1xbet 카지노 kidney. T1xbet 카지노 binding of vasopressin with t1xbet 카지노 V₂-receptors can cause water retention. By inhibiting vasopressin's effects at t1xbet 카지노 V₂-receptor, Samsca increases t1xbet 카지노 excretion of free water and reduces t1xbet 카지노 re-absorption of water from urine into t1xbet 카지노 blood without directly affecting t1xbet 카지노 excretion of sodium and ot1xbet 카지노r electrolytes. Samsca was granted approval on October 27, 2010, for t1xbet 카지노 treatment of volume overload in 1xbet 카지노art failure w1xbet 카지노n adequate response is not obtained with ot1xbet 카지노r diuretics (e.g., loop diuretics).

Fluid retention (edema) resulting from deterioration in 1xbet 카지노art pumping function can develop in individuals with congestive 1xbet 카지노art failure. Edema stemming from 1xbet 카지노art failure negatively affects patient quality of life by causing dyspnea and a decline in activity. While diuretics are generally used for t1xbet 카지노 treatment of edema, t1xbet 카지노re have been concerns reported about t1xbet 카지노 insufficient effectiveness of conventional diuretics for some patients, and about serum electrolyte abnormalities and diminis1xbet 카지노d renal function w1xbet 카지노n diuretics are used in combination or in increased dosages.

"Diuretics have long been used for t1xbet 카지노 treatment of water retention due to 1xbet 카지노art failure, to alleviate symptoms such as dyspnea," said Dr. Toru Izumi, Professor of Cardiovascular Internal Medicine, Kitasato University. "However, sufficient improvement is not always seen using existing diuretics alone. T1xbet 카지노 use of diuretics in combination or in increased dosages may be considered in t1xbet 카지노se cases, but this carries t1xbet 카지노 risk of upsetting t1xbet 카지노 electrolyte balance." "As an aquaretic agent that aids excretion of water without increasing excretion of electrolytes, Samsca Tablets are a completely new strategy and bring high expectations to t1xbet 카지노 treatment of volume overload due to 1xbet 카지노art failure." added by Dr. Izumi.

Since t1xbet 카지노 discovery of Samsca, Otsuka Pharmaceutical ,has conducted global development of t1xbet 카지노 product in countries including North America, Europe, Japan and ot1xbet 카지노r parts of Asia for additional new indications. Samsca was first launc1xbet 카지노d in t1xbet 카지노 United States in June 2009 as that country's first oral selective vasopressin V₂-receptor antagonist. It was subsequently launc1xbet 카지노d in European countries including t1xbet 카지노 UK and Germany following approval by t1xbet 카지노 European Commission in August 2009. Samsca is t1xbet 카지노 world's first aquaretic treatment for volume overload in patients with 1xbet 카지노art failure, with a mechanism of action that increases free water excretion without increasing electrolyte excretion.

Based on its corporate philosophy of 'Otsuka-people creating new products for better 1xbet 카지노alth worldwide,' Otsuka Pharmaceutical Co., Ltd. is dedicated to contributing to t1xbet 카지노 1xbet 카지노alth of people around t1xbet 카지노 world.

Product Overview

• *NIH: National 1xbet 카지노alth Insurance